22 unknown. 22 Phase 2, 9 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 22 | Unknown 22 |
| Phase 1 | 9 | Unknown 9 |
| Phase 3 | 3 | Unknown 3 |
Follow Glaucoma: new trials by email Literature Review of Glaucoma trials Research Report on Glaucoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized, Open-label, Active-controlled, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-angle Glaucoma or Ocular Hypertension TFC-003, COSOPT ophthalmic solution - Primary Open Angle Glaucoma, Ocular Hypertension | Phase 2 | Unknown | Kukje Pharma | 60 | 2024-02-01 | 2023-12-20 |
| A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma AMDX-2011P - Primary Open Angle Glaucoma | Phase 2 | Unknown | Amydis Inc. | 50 | 2023-12-07 | 2024-07-30 |
| Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension Travoprost Ophthalmic Topical Cream low-dose, Travoprost Ophthalmic Topical Cream mid-dose, Travoprost Ophthalmic Topical Cream high-dose - Open Angle Glaucoma, Ocular Hypertension | Phase 2 | Unknown | Glaukos Corporation | 250 | 2023-11-15 | 2023-12-06 |
| A Study to Investigate the Effect of IOP-lowering With TO-O-1001 Eye Drops in Healthy Subjects and in Patients With Open-Angle Glaucoma or Ocular Hypertension TO-O-1001, Placebo - Open Angle Glaucoma, Ocular Hypertension | Phase 1 / Phase 2 | Unknown | Theratocular Biotek Co. | 50 | 2022-08-04 | 2023-10-19 |
| A Clinical Study to Evaluate the Efficacy and Safety of CKD-351 CKD-351, Latanoprost+Dorzolmamide - Primary Open Angle Glaucoma, Ocular Hypertension | Phase 2 | Unknown | Chong Kun Dang Pharmaceutical | 100 | 2020-06-11 | 2020-06-25 |
| Treatment of Patients With Optic Nerve Damage Patients Using Electrostimulation Transorbital electrical stimulation - Glaucoma, Electrical Stimulation | Phase 1 / Phase 2 | Unknown | University of Magdeburg | 50 | 2019-08-05 | 2019-10-03 |
| Outcomes Mandate National Integration With Cannabis as Medicine Cannabis, Medical, RYAH-Medtech Inhaler - Chronic Pain, Chronic Pain Syndrome | Phase 2 | Unknown | OMNI Medical Services, LLC | 200000 | 2018-12-01 | 2022-06-02 |
| Exploratory Trial to Evaluate the Efficacy and Safety of D565H Twice Daily Versus D565 Once Daily D565H(Latanoprost 25㎍/㎖), D565(Latanoprost 50㎍/㎖) - Glaucoma, Primary Open Angle, Ocular Hypertension | Phase 2 | Unknown | Chong Kun Dang Pharmaceutical | 98 | 2017-03-30 | 2017-07-21 |
| Ahmed Glaucoma Valve Implantation; Graft-Free Short Tunnel Small Flap Versus Scleral Patch Graft Conventional scleral patch graft glaucoma implantation, New surgical method (short tunnel small flap technique) - Glaucoma | Phase 1 / Phase 2 | Unknown | Shahid Beheshti University of Medical Sciences | 80 | 2017-01-20 | 2018-06-11 |
| Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG aganirsen - Ischaemic Central Retinal Vein Occlusion, Neovascular Glaucoma | Phase 2 / Phase 3 | Unknown | Gene Signal SAS | 333 | 2017-01-01 | 2016-10-31 |
| Analysis of Aqueous and Vitreous Humor Ranibizumab, No Ranibizumab - Proliferative Diabetic Retinopathy, Macular Degeneration | Phase 2 | Unknown | California Retina Consultants | 45 | 2015-07-01 | 2017-03-01 |
| Effects of Magnetic Therapy and Seawater Combined in Decreasing Intraocular Presion. Pulsed Electromagnetic Field Therapy, Seawater eyedrops - Primary Open Angle Glaucoma, Hypertension Ocular | Phase 1 / Phase 2 | Unknown | American Society Of Thermalism And Climatology Inc | 100 | 2014-11-01 | 2015-06-23 |
| A Compassionate Case Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Glaucoma Patients With Uncontrolled Intraocular Pressure to Avoid Surgical Intervention Rho-Kinase Inhibitor (AR-12286) - Glaucoma | Phase 2 | Unknown | New York Glaucoma Research Institute | 10 | 2014-06-01 | 2015-04-24 |
| Effectiveness and Safety of Adipose-Derived Regenerative Cells for Treatment of Glaucomatous Neurodegeneration Subtenon administration of autologous ADRC, Liposuction, ADRC isolation - Retinal Degeneration, Primary Open-Angle Glaucoma | Phase 1 / Phase 2 | Unknown | Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation | 16 | 2014-05-01 | 2017-07-21 |
| Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension Stage 1 - ATS907 - Dose 1, Stage 1 - ATS907 - Dose 2, Stage 1 - ATS907 - Dose 3 - Primary Open Angle Glaucoma, Ocular Hypertension | Phase 1 / Phase 2 | Unknown | Altheos, Inc. | 180 | 2012-01-01 | 2012-11-01 |
| Intraocular Pressure (IOP) Lowering Efficacy of Transdermal Latanoprost Therapy 0.005% Latanoprost dosed once. - Glaucoma | Phase 2 | Unknown | Nanduri, Padma, M.D., FACS | 22 | 2011-09-01 | 2011-08-31 |
| Intraocular Pressure (IOP) Lowering Efficacy of Transdermal Brimonidine Therapy Brimonidine, Placebo Lotion - Glaucoma | Phase 2 | Unknown | Nanduri, Padma, M.D., FACS | 22 | 2011-04-01 | 2011-05-02 |
| The Effect of Bevacizumab on the Trabeculectomy intraocular injections of bevacizumab - Glaucoma | Phase 2 / Phase 3 | Unknown | Samsung Medical Center | 40 | 2010-03-01 | 2010-05-26 |
| Aqueous Mushroom Extract and Intraocular Pressure OME - Glaucoma | Phase 1 / Phase 2 | Unknown | University of Benin | 42 | 2009-11-01 | 2009-11-25 |
| Goniocurettage as First Choice of Surgical Treatment in Chronic Open-Angle Glaucoma: Outcomes and Complications Goniocurettage - Open-Angle Glaucoma, Surgery | Phase 2 / Phase 3 | Unknown | Federal University of Minas Gerais | 32 | 2009-06-01 | 2012-01-18 |
Showing 20 of 22. Sign in to see all of them.
Glaucoma, Open-Angle (11) · Ocular Hypertension (8) · Glaucoma, Neovascular (2) · Acquired Immunodeficiency Syndrome (1) · Amyotrophic Lateral Sclerosis (1) · Anemia, Sickle Cell (1) · Anxiety Disorders (1) · Autistic Disorder (1) · Bipolar Disorder (1) · Brain Injuries, Traumatic (1) · COVID-19 (1) · Chronic Pain (1) · Chronic Traumatic Encephalopathy (1) · Colitis, Ulcerative (1)
Eye Diseases (22) · Ocular Hypertension (14) · Nervous System Diseases (2) · Retinal Diseases (2) · Anemia (1) · Anemia, Hemolytic (1) · Anemia, Hemolytic, Congenital (1) · Autism Spectrum Disorder (1) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Basal Ganglia Diseases (1) · Behavior (1) · Behavioral Symptoms (1) · Bipolar and Related Disorders (1)
AR-12286 (1) · Brimonidine Tartrate (1) · GS 101 (1) · Latanoprost (1) · Lipectomy (1) · Medical Marijuana (1) · Ranibizumab (1) · Timolol (1) · epigallocatechin gallate (1)
Chong Kun Dang Pharmaceutical (2) · Nanduri, Padma, M.D., FACS (2) · Altheos, Inc. (1) · American Society Of Thermalism And Climatology Inc (1) · Amydis Inc. (1) · California Retina Consultants (1) · Catholic University of the Sacred Heart (1) · Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation (1) · Federal University of Minas Gerais (1) · Gene Signal SAS (1) · Glaukos Corporation (1) · Kukje Pharma (1) · National University Hospital, Singapore (1) · New York Glaucoma Research Institute (1) · OMNI Medical Services, LLC (1)
United States (9) · South Korea (4) · Australia (1) · Brazil (1) · Germany (1) · Iran (1) · Italy (1) · Nigeria (1) · Russia (1) · Singapore (1)
Padma Nanduri, MD (2) · Alina K Drakon, MD (1) · Barbara Wirostko, MD (1) · Benedetto Falsini, MD (1) · Changwon Kee, M.D., Ph.D (1) · Dario Marangoni, M.D. (1) · David Bingaman (1) · Dr. Ryan O Lakin, MD JD (1) · Garis Silega (1) · Ilya I Eremin, MD, PhD (1) · Julia P Sotnikova, MD (1) · KiHo Park (1) · KiHo Park, MD (1) · Michael Boone, MD (1) · Paul Chew, FRCSEd,MMed (1)
PMID 10201583, PMID 10664926, PMID 12049574, PMID 19290537, PMID 2194358, PMID 22207522, PMID 2806924, PMID 28302155
2014 (1)